We are live on ! Find out more
CRSP icon

CRISPR Therapeutics
CRSP

433 hedge funds and large institutions have $3.52B invested in CRISPR Therapeutics in 2025 Q2 according to their latest regulatory filings, with 101 funds opening new positions, 127 increasing their positions, 101 reducing their positions, and 60 closing their positions.

New
Increased
Maintained
Reduced
Closed

68% more first-time investments, than exits

New positions opened: 101 | Existing positions closed: 60

60% more capital invested

Capital invested by funds: $2.2B → $3.52B (+$1.32B)

31% more call options, than puts

Call options by funds: $244M | Put options by funds: $186M

26% more repeat investments, than reductions

Existing positions increased: 127 | Existing positions reduced: 101

9% more funds holding

Funds holding: 396 → 433 (+37)

8.4% more ownership

Funds ownership: 75.39% → 83.79% (+8.4%)

0% more funds holding in top 10

Funds holding in top 10: 6 → 6 (0)

Holders
433
Holders Change
+37
Holders Change %
+9.34%
% of All Funds
5.7%
Holding in Top 10
6
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.08%
New
101
Increased
127
Reduced
101
Closed
60
Calls
$244M
Puts
$186M
Net Calls
+$58.2M
Net Calls Change
+$37.5M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$134M
2
OAG
Orbis Allan Gray
Bermuda
+$46.5M
3
Geode Capital Management
Geode Capital Management
Massachusetts
+$39.7M
4
State Street
State Street
Massachusetts
+$33.3M
5
UBS Group
UBS Group
Switzerland
+$29.9M

Top Sellers

Rank Fund Capital Flow
1
UBS AM
UBS AM
Illinois
-$38.2M
2
Morgan Stanley
Morgan Stanley
New York
-$30.5M
3
BBA
Baker Bros. Advisors
New York
-$22.3M
4
Millennium Management
Millennium Management
New York
-$19.9M
5
Capital International Investors
Capital International Investors
California
-$18.6M
Name Holding Trade Value Shares
Change 		Change in
Stake
Northwestern Mutual Wealth Management
201
Northwestern Mutual Wealth Management
Wisconsin
$359K +$19.6K +507 +7%
QWM
202
Quadcap Wealth Management
Texas
$358K -$9.4K -243 -3%
ACM
203
Aquatic Capital Management
Illinois
$358K -$3.56M -91,972 -93%
1WA
204
180 Wealth Advisors
Washington
$357K +$38.5K +996 +16%
SIC
205
SFE Investment Counsel
California
$352K +$28.1K +725 +11%
Parallax Volatility Advisers
206
Parallax Volatility Advisers
California
$342K +$272K +7,035 New
CAI
207
Capital Advisors Inc
Oklahoma
$340K -$11.6M -300,506 -98%
WIM
208
Westside Investment Management
California
$340K -$36.8K -952 -12%
PGFC
209
Peapack-Gladstone Financial Corp
New Jersey
$339K +$7.74K +200 +3%
MWAM
210
Manhattan West Asset Management
California
$333K +$265K +6,843 New
RS
211
R Squared
Hong Kong
$329K +$262K +6,770 New
ICP
212
Interchange Capital Partners
Pennsylvania
$327K -$27.1K -699 -9%
MF
213
Magnetar Financial
Illinois
$319K +$254K +6,556 New
Cerity Partners
214
Cerity Partners
New York
$318K +$7.35K +190 +3%
X
215
Xponance
Pennsylvania
$314K +$250K +6,449 New
VFA
216
Valeo Financial Advisors
Indiana
$304K +$242K +6,245 New
AF
217
Advisornet Financial
Minnesota
$298K +$41K +1,060 +21%
LIA
218
Limestone Investment Advisors
New York
$297K +$236K +6,100 New
PFS
219
Prospera Financial Services
Texas
$297K +$236K +6,098 New
Mitsubishi UFJ Asset Management
220
Mitsubishi UFJ Asset Management
Japan
$296K +$14.2K +366 +6%
HIP
221
HUB Investment Partners
Texas
$295K -$1.66K -43 -0.7%
CL
222
Choreo LLC
Illinois
$293K +$233K +6,015 New
Wealthfront Advisers
223
Wealthfront Advisers
California
$292K +$232K +6,003 New
MAC
224
Mason & Associates (California)
California
$287K – – –
IP
225
Intellectus Partners
California
$284K +$226K +5,845 New
7 8
9
10 11

CRSP Hedge Fund Activity: Q2 2025 in Review

433 of the 7,595 institutional investors tracked by Wall St. Rank reported a position in CRISPR Therapeutics (CRSP) for Q2 2025, worth a combined $3.52B — up 60% from $2.2B a quarter earlier.

Buyers outnumbered sellers: 101 funds opened new CRSP positions and 60 closed out — a net gain of 41 holders — while 127 added to existing stakes and 101 trimmed.

The largest buyer was BlackRock, adding an estimated $134M. The largest seller was UBS AM, cutting an estimated $38.2M.

  • 433 institutional investors held CRISPR Therapeutics (CRSP) as of Q2 2025, up from 396 in Q1 2025.
  • Funds reported $3.52B of CRISPR Therapeutics stock for Q2 2025, up 60% quarter-over-quarter.
  • 101 funds opened new CRISPR Therapeutics positions in Q2 2025 and 60 closed out, a net change of +41 holders.
  • The largest CRISPR Therapeutics buyer in Q2 2025 was BlackRock, an estimated $134M added.
  • The largest CRISPR Therapeutics seller in Q2 2025 was UBS AM, an estimated $38.2M sold.

Based on aggregated 13F filings for Q2 2025.